Neuspera Medical has secured a $12m extension to bring its series B round to the targeted $26m close, with all investors from the first tranche returning.

Neuspera Medical, a US-based neuromodulation device developer based on research at Stanford University, yesterday raised $12m in additional series B capital to bring the round to its targeted $26m close. The extension was supplied by 6 Dimensions Capital, an investment firm backed by medical research firm WuXi PharmaTech, together with Action Potential Venture Capital, Windham…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.